Secondary Navigation Menu

Audience Switcher Modal

Country and Audience Choose Modal

Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.

Scientific Congress Publications

Supported by Bayer Pharmaceuticals

EMUC 2026

Risk of major adverse cardiovascular events (MACE) with darolutamide versus enzalutamide in patients with advanced prostate cancer: A real-world observational study
Date:
November 5, 2026
Type:
Poster
Presenting Author:
Hannah D. McManus
Download the Poster View the Video More info
Measuring the impact of fatigue on health-related quality of life in prostate cancer patients in the USA and Germany
Date:
October 25, 2026/2:46 PM – 2:48 PM
Session:
Poster Session 3- Sexual Medicine, Pediatric Urology & Clinical Trials
Type:
Poster
Presenting Author:
Daniel Sentana-Lledo
Download the Poster Download the Supplement View the Video More info
Back to Oncology

© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.

Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.

Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.

For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/

PP-GEN-ALL-0014-1